Title:Exploring Potential of Nano-formulations in the Treatment of Alzheimer’s
Disease through Nasal Route
Volume: 21
Author(s): Avinash Tekade*, Prasad Kadam, Sachin Jagdale, Samiksha Surwade, Anil Gaikwad, Parth Pawar and Rushikesh Shinde
Affiliation:
- Department of Pharmaceutics, Marathwada Mitra Mandal’s College of Pharmacy, Pune, India
Keywords:
Alzheimer’s disease, novel approaches, nose-to-brain delivery, challenges, drug product development, nano-formulations.
Abstract: Objective: Alzheimer's disease, a progressive neurodegenerative disorder, severely impacts
cognitive function and daily living. The current treatment provides only symptomatic relief,
and thus, disease-modifying therapies targeting underlying causes are needed. Although several
potential therapies are in various stages of clinical trials, bringing a new Alzheimer's drug to market
remains challenging. Hence, researchers are also exploring monoclonal antibodies, tau protein
inhibitors, and anti-inflammatory drugs as treatment options. Conventionally designed dosage
forms come with limitations like poor absorption, first-pass metabolism, and low bioavailability.
They also cause systemic adverse effects because these designed systems do not provide target-
specific drug delivery. Thus, in this review, the authors highlighted the current advancements
in the development of intranasal nanoformulations for the treatment of Alzheimer’s disease. This
strategy of delivering anti-Alzheimer drugs through the nasal route may help to target the drug exactly
to the brain, achieve rapid onset of action, avoid first-pass metabolism, and reduce the side
effects and dose required for administration.
Conclusion: Delivering drugs to the brain through the nasal route for treating Alzheimer's disease
is crucial due to the limited efficacy of existing treatments and the profound impact of the disease
on patients and their families. Thus, by exploring innovative approaches such as nose-to-brain
drug delivery, it is possible to improve the quality of life for individuals living with Alzheimer's
and alleviate its societal burden.
